ESMO 2024: Exact Sciences unveils results from cancer algorithm trial [Yahoo! Finance]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
cancer (CRC) screening test algorithm showed a sensitivity of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity. Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the real-world, prospective performance of the test. The study used more than 3,000 blood samples, including approximately 2,900 blinded prospectively collected samples from the company's pivotal BLUE-C study of its Cologuard Plus system which included more than 20,000 participants. The company said that the results show the potential of a novel, highly discriminate blood-based panel of methylated DNA markers in detecting advanced precancerous lesions and cancers while maintaining a low-cost profile, with the company confirming that it is now pushing ahead in seeking a US Food and Drug Administration (FDA) submission. Paul Limburg, chief med
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences gains 6% following data on blood-based colorectal cancer test [Seeking Alpha]Seeking Alpha
- Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024Business Wire
- Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $75.00 price target on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Piper Sandler from $75.00 to $85.00. They now have an "overweight" rating on the stock.MarketBeat
EXAS
Earnings
- 7/31/24 - Beat
EXAS
Sec Filings
- 9/19/24 - Form 4
- 9/18/24 - Form 144
- 8/6/24 - Form 4
- EXAS's page on the SEC website